Clinical trials: Pulmonary Hypertension, Primary, 4
Pulmonary Arterial Hypertension
A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)
Researchers are looking for other ways to treat people in India with pulmonary arterial hypertension (PAH), also known as Group 1 pulmonary hypertension (PH).
- Trial name
- NCT07600723
- Testing
- Sotatercept, Background PAH Therapy
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Pulmonary
Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years
This is an observational study to monitor the continued effectiveness of Ventavis (inhaled iloprost) in the long-term. The study observes the effects and the safety of Ventavis inhalation therapy over at least 2 years and up to 4…
- Trial name
- NCT00250640
- Testing
- Iloprost (Ventavis, BAYQ6256)
- Where
- 43 sites in France, Germany and 4 more
- Volunteers
- 106 people
- Sponsor
- Bayer
Pulmonary Hypertension, Bronchopulmonary Dysplasia
Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death
OBJECTIVES: I. Describe the psychosocial response of parents and caretakers who learn cardiopulmonary resuscitation (CPR) techniques for infants at high risk for respiratory or cardiac arrest. II.
- Conditions
- Pulmonary Hypertension, Bronchopulmonary Dysplasia, Respiratory Distress Syndrome
- Trial name
- NCT00004805
- Testing
- CPR instruction
- Volunteers
- 500 people
- Sponsor
- National Center for Research Resources (NCRR)
Pulmonary Arterial Hypertension
REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension
The study evaluates the effect of macitentan on right ventricular and hemodynamic properties in patients with symptomatic pulmonary arterial hypertension. Patients are treated with macitentan for 1 year.
- Trial name
- REPAIR (NCT02310672)
- Testing
- Macitentan
- Where
- 41 sites in United States, Australia and 10 more
- Volunteers
- 89 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Apabetalone for Pulmonary Arterial Hypertension: a Pilot Study
The main OBJECTIVE of this proposal is to extend the investigator's preclinical findings on the role of epigenetics and DNA damage and Bromodomain-Containing Protein 4 (BRD4) inhibition as a therapy for a devastating disease…
- Trial name
- APPRoAcH-p (NCT03655704)
- Testing
- Apabetalone
- Where
- 2 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Steeve Provencher
Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I
Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE)
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by vascular remodelling resulting in elevated pressures in the pulmonary artery (PA).
- Conditions
- Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I, Pulmonary Arterial Hypertension
- Trial name
- RECOMPENSE (NCT06658522)
- Testing
- Sotatercept
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Amsterdam UMC, location VUmc
Pulmonary Arterial Hypertension
Apabetalone for Pulmonary Arterial Hypertension
Throughout the past twenty years, numerous specific pharmacologic agents targeting the endothelial dysfunction associated with PAH have emerged.
- Trial name
- APPROACH-2 (NCT04915300)
- Testing
- Apabetalone
- Where
- Canada
- Volunteers
- 72 people
- Sponsor
- Laval University
Pulmonary Arterial Hypertension
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in…
- Trial name
- ARTISAN (NCT05203510)
- Testing
- Parenteral Treprostinil, Oral Treprostinil
- Where
- 28 sites in United States
- Volunteers
- 52 people
- Sponsor
- United Therapeutics
Cardiovascular Disease, Pulmonary Arterial Hypertension
Effect of BIA 5 1058 on Cardiac Repolarization
The purpose is to evaluate the effect of single therapeutic (400 mg) and supratherapeutic (1200 mg) doses of BIA 5-1058 on the time-matched change from baseline in placebo-adjusted interval corrected (QT) for heart rate (HR)
- Conditions
- Cardiovascular Disease, Pulmonary Arterial Hypertension, Heart Failure
- Trial name
- NCT03489005
- Testing
- BIA 5-1058, Moxifloxacin 400 mg
- Where
- United Kingdom
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System
Ventavis it's a treatment for pulmonary hypertension, administered by an inhaler called I-Neb. In these patients, the non compliance of the treatment becomes its ineffective and increases the complications and mortality of the…
- Trial name
- Inventa (NCT01468545)
- Testing
- Iloprost (Ventavis inhaled, BAYQ6256)
- Where
- Spain
- Volunteers
- 38 people
- Sponsor
- Bayer
Chronic Right-Sided Heart Failure, Pulmonary Arterial Hypertension
Spironolactone Therapy in Chronic Stable Right HF Trial
The purpose of this study is to evaluate the safety, tolerability and mechanistic effects of spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity and right heart function and remodeling in…
- Conditions
- Chronic Right-Sided Heart Failure, Pulmonary Arterial Hypertension, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3
- Trial name
- STAR-HF (NCT03344159)
- Testing
- Spironolactone, PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82, Cardiac MRI (Gadolinium enhanced)
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Pulmonary Hypertension, Primary, 4
Serum Bio-markers in Pulmonary Hypertension
Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by scarred blood clots in the blood vessels supplying the lungs. This in turn leads to failure of the right side of the heart.
- Trial name
- NCT04472533
- Where
- United Kingdom
- Volunteers
- 377 people, healthy volunteers welcome
- Sponsor
- Papworth Hospital NHS Foundation Trust
Pulmonary Hypertension Group 1 and 4 According to Nice Classification
NIMS- New Implantable Pump in Pulmonary Arterial Hypertension, a Safety Follow up
This observational study aims to chart patients which get their prostacyclin treatment via the subcutaneous LenusPro pump. How the surgical procedure is performed and the clinical follow-up of these patients.
- Trial name
- NCT01977014
- Where
- 8 sites in Denmark, Norway and 1 more
- Volunteers
- 40 people
- Sponsor
- NordicInfu Care AB
Hypertension, Pulmonary
A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).
The Study Hypothesis: Aggressive, upfront, dual therapy for treatment-naïve NYHA I/II/III PAH is superior to a traditional "step-up" approach. The study will evaluate: 1.
- Trial name
- NCT01305252
- Testing
- treprostinil inhalations, tadalafil
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Stanford University
Pulmonary Arterial Hypertension
A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging
The purpose of the study is to assess the effects of selexipag on right ventricular (RV) function in participants with Pulmonary arterial hypertension (PAH).
- Trial name
- RESTORE (NCT04435782)
- Testing
- JNJ-67896049
- Where
- 35 sites in United States, Argentina and 13 more
- Volunteers
- 9 people
- Sponsor
- Actelion
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Pulmonary Hypertension Biorepository and Registry
Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary
- Trial name
- PHBR (NCT04808596)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Kansas Medical Center
Pulmonary Arterial Hypertension
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
The primary objective of this study is to evaluate the effect of selexipag on the physical activity of patients with pulmonary arterial hypertension (PAH) in their daily life, by using a wearable wrist device (actigraph).
- Trial name
- TRACE (NCT03078907)
- Testing
- Selexipag
- Where
- 39 sites in United States, Austria and 8 more
- Volunteers
- 108 people
- Sponsor
- Actelion